GSK logo

GSK plc (GSK) Cash From Financing

Annual CFF:

-$5.24B+$825.72M(+13.61%)
December 31, 2024

Summary

  • As of today, GSK annual cash from financing is -$5.24 billion, with the most recent change of +$825.72 million (+13.61%) on December 31, 2024.
  • During the last 3 years, GSK annual cash from financing has risen by +$4.14 billion (+44.14%).
  • GSK annual cash from financing is now -206.96% below its all-time high of $4.90 billion, reached on December 31, 2018.

Performance

GSK Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherGSKcash flow metrics

Quarterly CFF:

-$2.78B-$4.02B(-323.90%)
June 30, 2025

Summary

  • As of today, GSK quarterly cash from financing is -$2.78 billion, with the most recent change of -$4.02 billion (-323.90%) on June 30, 2025.
  • Over the past year, GSK quarterly cash from financing has dropped by -$1.12 billion (-67.66%).
  • GSK quarterly cash from financing is now -123.89% below its all-time high of $11.63 billion, reached on June 30, 2018.

Performance

GSK Quarterly Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherGSKcash flow metrics

TTM CFF:

-$3.92B-$1.12B(-40.03%)
June 30, 2025

Summary

  • As of today, GSK TTM cash from financing is -$3.92 billion, with the most recent change of -$1.12 billion (-40.03%) on June 30, 2025.
  • Over the past year, GSK TTM cash from financing has increased by +$5.22 billion (+57.11%).
  • GSK TTM cash from financing is now -138.76% below its all-time high of $10.11 billion, reached on March 31, 2019.

Performance

GSK TTM Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherGSKcash flow metrics

Cash From Financing Formula

CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities

GSK Cash From Financing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1Y1 Year+13.6%-67.7%+57.1%
3Y3 Years+44.1%+51.3%-3476.1%
5Y5 Years-338.1%+1.2%+68.4%

GSK Cash From Financing Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs LowTTM vs HighTTM vs HighTTM vs LowTTM vs Low
3Y3-Year-355.9%+44.1%-323.9%+31.6%-292.9%+57.1%
5Y5-Year-355.9%+55.9%-125.7%+51.3%-222.7%+68.5%
All-TimeAll-Time-207.0%+55.9%-123.9%+51.3%-138.8%+68.5%

GSK Cash From Financing History

DateAnnualQuarterlyTTM
Jun 2025
-
-$2.78B(-323.9%)
-$3.92B(-40.0%)
Mar 2025
-
$1.24B(+246.8%)
-$2.80B(+47.1%)
Dec 2024
-$5.24B(+13.6%)
-$845.20M(+45.1%)
-$5.29B(+37.8%)
Sep 2024
-
-$1.54B(+7.1%)
-$8.51B(+6.9%)
Jun 2024
-
-$1.66B(-32.1%)
-$9.14B(-29.8%)
Mar 2024
-
-$1.25B(+69.1%)
-$7.04B(-16.6%)
Dec 2023
-$6.07B(-396.3%)
-$4.06B(-87.5%)
-$6.04B(-83.7%)
Sep 2023
-
-$2.17B(-592.9%)
-$3.29B(-14.7%)
Jun 2023
-
$439.58M(+276.5%)
-$2.87B(+68.2%)
Mar 2023
-
-$249.08M(+81.0%)
-$9.01B(-543.3%)
Dec 2022
$2.05B(+121.8%)
-$1.31B(+24.9%)
$2.03B(>+9900.0%)
Sep 2022
-
-$1.75B(+69.4%)
$14.09M(+112.8%)
Jun 2022
-
-$5.70B(-152.8%)
-$109.63M(-103.4%)
Mar 2022
-
$10.79B(+424.2%)
$3.19B(+134.1%)
Dec 2021
-$9.39B(+21.1%)
-$3.33B(-78.0%)
-$9.37B(-9.4%)
Sep 2021
-
-$1.87B(+22.0%)
-$8.57B(+28.7%)
Jun 2021
-
-$2.40B(-35.0%)
-$12.02B(+3.3%)
Mar 2021
-
-$1.78B(+29.7%)
-$12.43B(-4.6%)
Dec 2020
-$11.89B(-893.5%)
-$2.53B(+52.5%)
-$11.88B(+4.3%)
Sep 2020
-
-$5.32B(-89.1%)
-$12.42B(-31.8%)
Jun 2020
-
-$2.81B(-129.5%)
-$9.42B(-28.5%)
Mar 2020
-
-$1.23B(+60.0%)
-$7.33B(-518.4%)
Dec 2019
-$1.20B(-124.4%)
-$3.06B(-32.1%)
-$1.19B(+43.6%)
Sep 2019
-
-$2.32B(-220.3%)
-$2.10B(+5.9%)
Jun 2019
-
-$724.11M(-114.7%)
-$2.23B(-122.1%)
Mar 2019
-
$4.92B(+223.6%)
$10.11B(+105.0%)
Dec 2018
$4.90B(+168.1%)
-$3.98B(-62.3%)
$4.93B(-5.4%)
Sep 2018
-
-$2.45B(-121.1%)
$5.22B(-23.5%)
Jun 2018
-
$11.63B(+4567.5%)
$6.82B(+219.9%)
Mar 2018
-
-$260.23M(+93.0%)
-$5.69B(+20.8%)
Dec 2017
-$7.20B(+6.3%)
-$3.70B(-334.8%)
-$7.18B(-55.3%)
Sep 2017
-
-$850.57M(+2.9%)
-$4.62B(+36.7%)
Jun 2017
-
-$876.28M(+50.1%)
-$7.30B(+5.2%)
Mar 2017
-
-$1.75B(-53.8%)
-$7.70B(-0.2%)
Dec 2016
-$7.69B(+20.2%)
-$1.14B(+67.7%)
-$7.69B(+6.5%)
Sep 2016
-
-$3.53B(-176.4%)
-$8.22B(-18.8%)
Jun 2016
-
-$1.28B(+26.5%)
-$6.92B(+21.7%)
Mar 2016
-
-$1.74B(-3.9%)
-$8.84B(+8.7%)
Dec 2015
-$9.64B(-25.1%)
-$1.67B(+25.0%)
-$9.68B(+4.6%)
Sep 2015
-
-$2.23B(+30.2%)
-$10.14B(-24.8%)
Jun 2015
-
-$3.20B(-24.1%)
-$8.13B(-32.3%)
Mar 2015
-
-$2.58B(-20.5%)
-$6.14B(+7.2%)
Dec 2014
-$7.70B(+0.4%)
-$2.14B(-894.5%)
-$6.62B(+0.8%)
Sep 2014
-
-$214.98M(+82.3%)
-$6.67B(+16.4%)
Jun 2014
-
-$1.21B(+60.3%)
-$7.98B(+16.2%)
Mar 2014
-
-$3.05B(-39.3%)
-$9.52B(-23.2%)
Dec 2013
-$7.73B(-90.7%)
-$2.19B(-43.4%)
-$7.73B(-17.1%)
Sep 2013
-
-$1.53B(+44.5%)
-$6.60B(+4.3%)
Jun 2013
-
-$2.75B(-118.2%)
-$6.90B(-97.9%)
Mar 2013
-
-$1.26B(-18.8%)
-$3.49B(+14.0%)
Dec 2012
-$4.05B(+53.7%)
-$1.06B(+41.9%)
-$4.06B(+8.6%)
Sep 2012
-
-$1.83B(-375.9%)
-$4.44B(+19.8%)
Jun 2012
-
$662.37M(+136.2%)
-$5.53B(+34.6%)
Mar 2012
-
-$1.83B(-26.7%)
-$8.46B(+3.8%)
Dec 2011
-$8.76B
-$1.45B(+50.5%)
-$8.80B(-1.8%)
DateAnnualQuarterlyTTM
Sep 2011
-
-$2.92B(-28.9%)
-$8.64B(-25.0%)
Jun 2011
-
-$2.27B(-4.9%)
-$6.91B(+2.3%)
Mar 2011
-
-$2.16B(-67.7%)
-$7.07B(+4.4%)
Dec 2010
-$7.40B(-136.6%)
-$1.29B(-8.0%)
-$7.40B(+5.7%)
Sep 2010
-
-$1.19B(+50.9%)
-$7.85B(-68.4%)
Jun 2010
-
-$2.43B(+2.4%)
-$4.66B(+7.5%)
Mar 2010
-
-$2.49B(-43.1%)
-$5.04B(-61.0%)
Dec 2009
-$3.13B(+48.1%)
-$1.74B(-187.1%)
-$3.13B(+3.0%)
Sep 2009
-
$2.00B(+171.2%)
-$3.23B(+62.8%)
Jun 2009
-
-$2.81B(-383.2%)
-$8.67B(-662.6%)
Mar 2009
-
-$580.56M(+68.4%)
-$1.14B(+81.1%)
Dec 2008
-$6.02B(-107.9%)
-$1.84B(+46.8%)
-$6.02B(-303.6%)
Sep 2008
-
-$3.45B(-172.9%)
-$1.49B(-172.3%)
Jun 2008
-
$4.73B(+186.5%)
-$548.18M(+92.4%)
Mar 2008
-
-$5.47B(-302.9%)
-$7.26B(-149.6%)
Dec 2007
-$2.90B(+64.0%)
$2.70B(+207.6%)
-$2.91B(+60.3%)
Sep 2007
-
-$2.50B(-26.3%)
-$7.32B(-12.6%)
Jun 2007
-
-$1.98B(-77.7%)
-$6.50B(+11.9%)
Mar 2007
-
-$1.12B(+35.0%)
-$7.37B(+7.7%)
Dec 2006
-$8.05B(-83.9%)
-$1.72B(-2.0%)
-$7.99B(+15.8%)
Sep 2006
-
-$1.68B(+41.1%)
-$9.49B(-3.3%)
Jun 2006
-
-$2.86B(-64.7%)
-$9.18B(-128.7%)
Mar 2006
-
-$1.73B(+46.0%)
-$4.02B(+8.5%)
Dec 2005
-$4.38B(+22.9%)
-$3.21B(-133.0%)
-$4.39B(-142.4%)
Sep 2005
-
-$1.38B(-159.7%)
-$1.81B(+33.4%)
Jun 2005
-
$2.31B(+209.6%)
-$2.72B(+49.9%)
Mar 2005
-
-$2.11B(-232.8%)
-$5.42B(+3.5%)
Dec 2004
-$5.68B(-27.1%)
-$633.91M(+72.3%)
-$5.62B(-5.3%)
Sep 2004
-
-$2.29B(-482.3%)
-$5.34B(-19.3%)
Jun 2004
-
-$392.51M(+83.0%)
-$4.47B(+20.3%)
Mar 2004
-
-$2.31B(-552.5%)
-$5.61B(-26.9%)
Dec 2003
-$4.47B(+26.0%)
-$353.53M(+75.1%)
-$4.42B(+7.9%)
Sep 2003
-
-$1.42B(+7.2%)
-$4.80B(-1.1%)
Jun 2003
-
-$1.53B(-36.8%)
-$4.75B(+15.7%)
Mar 2003
-
-$1.12B(-52.3%)
-$5.64B(+6.8%)
Dec 2002
-$6.04B(-8.7%)
-$734.38M(+46.4%)
-$6.06B(+24.7%)
Sep 2002
-
-$1.37B(+43.4%)
-$8.04B(-10.2%)
Jun 2002
-
-$2.42B(-58.0%)
-$7.29B(-16.1%)
Mar 2002
-
-$1.53B(+43.6%)
-$6.28B(-13.3%)
Dec 2001
-$5.56B(-29.3%)
-$2.72B(-335.8%)
-$5.54B(-51.7%)
Sep 2001
-
-$623.42M(+55.8%)
-$3.65B(-19.9%)
Jun 2001
-
-$1.41B(-77.8%)
-$3.05B(-81.7%)
Mar 2001
-
-$793.36M(+4.1%)
-$1.68B(-102.7%)
Dec 2000
-$4.30B(-22.4%)
-$827.58M(-4812.2%)
-$827.58M(>-9900.0%)
Sep 2000
-
-$16.85M(+57.2%)
$100.00(-100.0%)
Jun 2000
-
-$39.35M(-170.0%)
$16.85M(-70.0%)
Mar 2000
-
$56.19M
$56.19M
Dec 1999
-$3.51B(-146.4%)
-
-
Dec 1998
-$1.43B(+28.0%)
-
-
Dec 1997
-$1.98B(+25.5%)
-
-
Dec 1996
-$2.66B(-179.0%)
-
-
Dec 1995
$3.36B(+5659.7%)
-
-
Jun 1994
$58.39M(+108.1%)
-
-
Jun 1993
-$718.86M(+56.2%)
-
-
Jun 1992
-$1.64B(-265.1%)
-
-
Jun 1991
-$449.64M
-
-

FAQ

  • What is GSK plc annual cash from financing?
  • What is the all-time high annual cash from financing for GSK plc?
  • What is GSK plc annual cash from financing year-on-year change?
  • What is GSK plc quarterly cash from financing?
  • What is the all-time high quarterly cash from financing for GSK plc?
  • What is GSK plc quarterly cash from financing year-on-year change?
  • What is GSK plc TTM cash from financing?
  • What is the all-time high TTM cash from financing for GSK plc?
  • What is GSK plc TTM cash from financing year-on-year change?

What is GSK plc annual cash from financing?

The current annual cash from financing of GSK is -$5.24B

What is the all-time high annual cash from financing for GSK plc?

GSK plc all-time high annual cash from financing is $4.90B

What is GSK plc annual cash from financing year-on-year change?

Over the past year, GSK annual cash from financing has changed by +$825.72M (+13.61%)

What is GSK plc quarterly cash from financing?

The current quarterly cash from financing of GSK is -$2.78B

What is the all-time high quarterly cash from financing for GSK plc?

GSK plc all-time high quarterly cash from financing is $11.63B

What is GSK plc quarterly cash from financing year-on-year change?

Over the past year, GSK quarterly cash from financing has changed by -$1.12B (-67.66%)

What is GSK plc TTM cash from financing?

The current TTM cash from financing of GSK is -$3.92B

What is the all-time high TTM cash from financing for GSK plc?

GSK plc all-time high TTM cash from financing is $10.11B

What is GSK plc TTM cash from financing year-on-year change?

Over the past year, GSK TTM cash from financing has changed by +$5.22B (+57.11%)
On this page